Auris Medical Holding AG (EARS) Shares Up 0%
Auris Medical Holding AG (NASDAQ:EARS) shot up 0% on Monday . The stock traded as high as $0.75 and last traded at $0.68. 822,000 shares were traded during mid-day trading, an increase of 118% from the average session volume of 376,940 shares. The stock had previously closed at $0.68.
Separately, Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Wednesday, August 30th.
The company has a debt-to-equity ratio of 1.43, a current ratio of 2.56 and a quick ratio of 2.56.
Auris Medical Holding AG (NASDAQ:EARS) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.09. equities research analysts forecast that Auris Medical Holding AG will post -0.68 EPS for the current fiscal year.
An institutional investor recently bought a new position in Auris Medical Holding AG stock. Virtu KCG Holdings LLC bought a new position in Auris Medical Holding AG (NASDAQ:EARS) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical Holding AG as of its most recent SEC filing. 28.35% of the stock is currently owned by institutional investors.
WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/auris-medical-holding-ag-ears-shares-up-0/1705139.html.
Auris Medical Holding AG Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with Analyst Ratings Network's FREE daily email newsletter.